Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody
Authors:
- Gessica FilocamoGFGessica Filocamo
- Mariachiara BuccarelliMBMariachiara Buccarelli
- Armin LahmALArmin Lahm
- Mirko BrunettiMBMirko Brunetti
- Chantal PaoliniCPChantal Paolini
- Gabriele De LucaGLGabriele De Luca
- Michele SignoreMSMichele Signore
- Giorgia CastellaniGCGiorgia Castellani
- Alessandra BoeABAlessandra Boe
- Romina AlfonsiRARomina Alfonsi
- Mauro BiffoniMBMauro Biffoni
- Ruggero De MariaRMRuggero De Maria
Open Access
Abstract
Background/Objectives: The progression and dissemination of CRC are heavily influenced by a subpopulation of tumor cells known as CSCs. This study aimed to identify novel protein membrane antigens expressed by colorectal CSCs and the consequent development of targeted therapies based on monoclonal antibodies directed against the identified antigens. Methods: Integrated bioinformatics analyses were conducted using proprietary CSC gene expression profiles and public colon gene expression databases, leading to the identification of five plasma membrane proteins enriched in CSCs. Genetic immunization in rats was employed to generate monoclonal antibodies (mAbs) targeting these antigens. FGFR4 was prioritized due to its overexpression in colorectal tumors. Its function was characterized in vitro and in vivo through assays evaluating proliferation, colony formation, migration, and tumorigenicity. The anti-FGFR4 antibody 3B6 was selected based on its affinity and ability to inhibit FGFR4 signaling in CSCs. Its therapeutic potential was further assessed in xenograft models, and alterations in downstream signaling were analyzed via Western blot. Results: FGFR4 emerged as a key regulator of CRC CSC proliferation, migration, and tumorigenic capacity. The 3B6 antibody, a high-affinity FGFR4 binder, demonstrated robust in vitro inhibition of CSC features and significant antitumor effects in patient-derived xenograft models. Western blot analysis confirmed the modulation of FGFR4-driven signaling pathways, particularly those involved in epithelial–mesenchymal transition (EMT). Conclusions: This study successfully identified several CSC-selective membrane antigens that can become therapeutic targets in CRC. Among them, we focused on FGFR4 as a promising target and developed the anti-FGFR4 3B6 monoclonal antibody which offers potential for both diagnostic and therapeutic applications.Keywords
Funding Information
- European EuroTrans-Bio Grant (ETB-2011-03)
- National Plan for Complementary Investments to the NRRP (PNC0000001)
This publication has 101 references indexed in Scilit:
- FGF19‐Induced Inflammatory CAF Promoted Neutrophil Extracellular Trap Formation in the Liver Metastasis of Colorectal CancerAdvanced Science, 2023
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCCHepatology, 2021
- Short tandem repeat profiling for the authentication of cancer stem‐like cellsInternational Journal of Cancer, 2020
- Ileal FGF15 contributes to fibrosis‐associated hepatocellular carcinoma developmentInternational Journal of Cancer, 2014
- Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer CellsStem Cells, 2012
- Understanding the Structure-Function Relationship between FGF19 and Its Mitogenic and Metabolic Activities2012
- FGF19 and Cancer2012
- Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinomaMolecular Carcinogenesis, 2011
- Selective over‐expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancerThe Journal of Pathology, 2007
- Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinomaInternational Journal of Cancer, 2004